Program
fostemsavir
Also written as “BMS-663068”, “Fostemsavir” and “Fostemsavir 600 mg”.
Its studies are mostly in Infections · HIV Infections, led by GlaxoSmithKline.
Furthest: phase 3, since Feb 9, 201519 company-led studies, 2 open or runningNext primary completion: Sep 14, 2032 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 192 open or running | phase 3since Feb 9, 2015 | Nov 6, 2009 | Sep 14, 2032phase 3 · NCT07393659 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 6, 2009.
- May 13, 2014Phase 1 study in InfectionsNCT02138084 · 102 enrolled · United States
- Jun 12, 2014Phase 1 study in InfectionsNCT02164045 · 38 enrolled · United States
- Sep 5, 2014Phase 1 study in HIV InfectionsNCT02234882 · 50 enrolled
- Oct 27, 2014Phase 1 study in InfectionsNCT02277600 · 32 enrolled · United States
- Feb 9, 2015Phase 3 study in HIV InfectionsNCT02362503 · 371 enrolled · United States, Argentina, Australia and more
- May 20, 2015Phase 1 study in InfectionsNCT02467335 · 52 enrolled · United States
- Jun 16, 20152 phase 1 studies in InfectionsNCT02480894, NCT02480881
- Jul 22, 2015Phase 1 study in InfectionsNCT02508064 · 27 enrolled · United Kingdom
- Dec 21, 2015Phase 1 study in HIV InfectionsNCT02674581 · 30 enrolled · United States
- Jan 6, 20162 phase 1 studies in InfectionsNCT02666001, NCT02666053
- May 31, 2016Phase 1 study in InfectionsNCT02805556 · 36 enrolled · United Kingdom
- Jul 28, 2016Phase 1 study in InfectionsNCT02859259 · 14 enrolled · United States
- Feb 12, 2021Phase 1 study in HIV InfectionsNCT04757974 · 32 enrolled · United States
- Jan 30, 2026Phase 3 study in HIV InfectionsNCT07393659 · 197 planned · Romania, South Africa, Uganda
Ahead
- Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsNCT07393659
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Envelope polyprotein GP160 inhibitor; Envelope polyprotein GP160 inhibitor”ChEMBL 37, by rule
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07393659HIV Infections · Romania, South Africa, Uganda | 3 | Recruiting | Sep 14, 2032 | 197 |
| NCT04757974HIV Infections · United States | 1 | Completed | Jul 31, 2021 | 32 |
| NCT02859259Infections · United States | 1 | Completed | Aug 12, 2016 | 14 |
| NCT02805556Infections · United Kingdom | 1 | Completed | May 5, 2016 | 36 |
| NCT02666053Infections · United States | 1 | Completed | Feb 22, 2016 | 72 |
| NCT02666001Infections · United States | 1 | Completed | Jun 29, 2016 | 32 |
| NCT02674581HIV Infections · United States | 1 | Completed | May 24, 2016 | 30 |
| NCT02508064Infections · United Kingdom | 1 | Completed | Nov 5, 2015 | 27 |
| NCT02480881Infections · United States | 1 | Completed | Jan 11, 2016 | 26 |
| NCT02480894Infections · United States | 1 | Completed | Sep 21, 2015 | 112 |
| NCT02467335Infections · United States | 1 | Completed | Oct 3, 2015 | 52 |
| NCT02362503HIV Infections · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 18, 2016 | 371 |
| NCT02277600Infections · United States | 1 | Completed | Jan 12, 2015 | 32 |
| NCT02234882HIV Infections | 1 | Completed | Oct 31, 2014 | 50 |
| NCT02164045Infections · United States | 1 | Completed | Jul 25, 2014 | 38 |
| NCT02138084Infections · United States | 1 | Completed | Jul 24, 2014 | 102 |
| NCT02063360Infections | 1 | Completed | May 1, 2014 | 42 |
| NCT01384734Infections · United States, Argentina, Colombia and more | 2 | Completed | Feb 18, 2013 | 254 |
| NCT01009814HIV Infections · Germany | 2 | Completed | Jun 25, 2010 | 50 |
How it is read
Names in the registry
- “BMS-663068”, 14 entries
- “Fostemsavir”, 1 entry
- “Fostemsavir 600 mg”, 1 entry
- “Fostemsavir 200 mg”, 1 entry
- “BMS-663068 400 mg”, 1 entry
Conditions, from the studies’ own filings
- Infections, 13 studies
- HIV Infections, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.